KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib (2013)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1016/j.ejca.2013.02.023
- Subjects: NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA); MUTAÇÃO GENÉTICA; ESTUDOS RETROSPECTIVOS; PROGNÓSTICO; BIOMARCADORES; METÁSTASE NEOPLÁSICA
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Cancer
- ISSN: 0959-8049
- Volume/Número/Paginação/Ano: v. 49, n. 10, p. 2424-2432, 2013
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SMITH, John C. et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, v. 49, n. 10, p. 2424-2432, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2013.02.023. Acesso em: 27 jan. 2026. -
APA
Smith, J. C., Brooks, L., Hoff, P. M., McWalter, G., Dearden, S., Morgan, S. R., et al. (2013). KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, 49( 10), 2424-2432. doi:10.1016/j.ejca.2013.02.023 -
NLM
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023 -
Vancouver
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023 - Venous thromboembolism and cancer: a systematic review
- A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
- Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
- Reversible serum carcinoembriogenic antigen (CEA) elevation due to orlistat use [Carta]: a case report
- Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
- GIST retal em uso de imatinibe neoadjuvante com excelente resposta: relato de caso
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
- Estudo retrospectivo de prevalência de instabilidade de microssatélite em pacientes com câncer colorretal (CCR) não selecionados submetidos a cirurgia do tumor primário: análise de 212 pacientes do Instituto do Câncer do Estado de São Paulo - ICESP
- Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1
- Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports
Informações sobre o DOI: 10.1016/j.ejca.2013.02.023 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
